% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

  • snt951 snt951 Nov 1, 2013 10:18 PM Flag

    Enchant Partnership discussions - Last Quarterly Clinical update

    The ENCHANT program in breast cancer

    Some of the strongest evidence for the role of Hsp90 in fueling cancer growth is from breast cancer: reduced expression of tumor Hsp90 is associated with significantly longer patient survival [1].

    Based on the supportive scientific findings, evidence of single-agent clinical activity for ganetespib in triple-negative breast cancer, the widespread use of taxanes in this disease, and the positive results for ganetespib in combination with docetaxel in lung cancer, Synta has developed two registration programs focusing on triple-negative breast cancer. The first is in the metastatic setting, and the second is in the neo-adjuvant setting. Synta expects those programs to initiate in 2014, pending completion of certain ongoing partnership discussions.

    Recently announced clinical results from the ENCHANT-1 trial have confirmed prior signals of single-agent clinical activity. Synta expects results from ENCHANT-1 will be presented at a medical conference later this year.

0.3430.000(0.00%)Jul 22 3:59 PMEDT